Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative therapies for bipolar disorder.

B Lerer

    The Journal of Clinical Psychiatry
    |August 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Carbamazepine shows promise as an alternative treatment for bipolar disorder when lithium is ineffective or causes side effects. More research is needed to confirm its efficacy for manic-depressive illness.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree - CORRIGENDUM.

    The international journal of neuropsychopharmacology·2019
    Same author

    Differential effects of chronic stress in young-adult and old female mice: cognitive-behavioral manifestations and neurobiological correlates.

    Molecular psychiatry·2017
    Same author

    Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: translational evidence from the stress-resilient Ahi1 knockout mouse.

    Molecular psychiatry·2016
    Same author

    Searching for genes in Schizophrenia.

    Acta neuropsychiatrica·2016
    Same author

    Treatment of unipolar major depression: Algorithms for pharmacotherapy.

    International journal of psychiatry in clinical practice·2014
    Same author

    Amygdalar disconnectivity could underlie stress resilience in the Ahi1 knockout mouse: conclusions from a resting-state functional MRI study.

    Molecular psychiatry·2014
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Psychiatry and Pharmacology
    • Neuroscience and Behavioral Science

    Background:

    • Lithium is a primary treatment for bipolar disorder (manic-depressive illness).
    • A subset of patients do not respond to lithium or experience severe adverse effects.
    • Alternative treatments are sought for these non-responsive or intolerant patients.

    Purpose of the Study:

    • To evaluate the clinical efficacy of proposed alternative treatments for bipolar disorder.
    • To identify viable alternatives to lithium for managing manic-depressive illness.

    Main Methods:

    • Literature review and evaluation of evidence for alternative treatments.
    • Assessment of clinical applicability and efficacy data for various therapeutic options.

    Main Results:

    Related Experiment Videos

    • Carbamazepine is identified as a clinically applicable potential alternative to lithium.
    • Evidence for carbamazepine's antimanic and prophylactic efficacy requires further controlled studies for conclusive establishment.
    • Other theoretical treatments show potential but need more thorough evaluation.

    Conclusions:

    • Carbamazepine represents the most promising current alternative for bipolar disorder patients with lithium intolerance or non-response.
    • Further rigorous clinical trials are essential to solidify carbamazepine's role in bipolar disorder management.
    • Exploration of novel therapeutic strategies remains critical for comprehensive patient care.